Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

fluorouracil/irinotecan/levo-folinic acid/bevacizumab

standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks

Trial Locations (1)

00133

'Tor Vergata' University Hospital, Rome

All Listed Sponsors
lead

University of Rome Tor Vergata

OTHER

NCT01533740 - Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter